 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Osstem Implant said on the 28th that its consolidated operating profit for the third quarter of this year was tentatively tallied at 2,050 billion won, up 24.9 percent from a year earlier.
During the same period, sales rose 14.9 percent year-on-year to 8,953 billion won. Both operating profit and sales are the largest ever in the third quarter.
The company explained that it has achieved even growth in domestic and foreign markets. Among them, domestic sales reached 3,009 billion won, up 11.2% from the previous year, and overseas sales increased 16.9% to 5,944 billion won.
As growth in the global market became more prominent, the proportion of overseas sales soared to 66.4%. Looking at overseas market sales by region, the growth rate in the Americas was the highest at 22.1%. This reflects the positive performance of "HIOSSEN," a premium implant brand produced by the US corporation and supplied to the world. The focus of customized marketing on the characteristics of the US market, such as strengthening corporate DSO operations, was also the background of high growth.
Sales in Asia also grew 17.4% year-on-year, showing smooth growth.
It expects explosive growth in the future as it is rapidly expanding its sales network in Europe by opening a series of new subsidiaries in France, Italy, the Netherlands and Portugal in the first half of this year.
"With the transition to endemics, we are accelerating our sales by expanding clinical education and face-to-face operations for dentists around the world and increasing the number of invitation educational events in Korea," an Ostem Implant official said. "We will strengthen our strong education system and boost our digital capabilities to achieve our goal of becoming the world's No. 1 implant company in 2026."
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
